Precision BioSciences announces that its first-in-class gene therapy Pbgene-Dmd for Duchenne muscular dystrophy (DMD) has received Investigational New Drug (IND) application approval from the U.S. Food and Drug Administration (FDA).

Precision BioSciences announces that its first-in-class gene therapy Pbgene-Dmd for Duchenne muscular dystrophy (DMD) has received Investigational New Drug (IND) application approval from the U.S. Food and Drug Administration (FDA).

老虎证券2026/02/11 12:09

Show original

This important regulatory milestone paves the way for the therapy to enter the clinical research phase.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

PoolX: Earn new token airdrops

Lock your assets and earn 10%+ APR

Lock now!

Precision BioSciences announces that its first-in-class gene therapy Pbgene-Dmd for Duchenne muscular dystrophy (DMD) has received Investigational New Drug (IND) application approval from the U.S. Food and Drug Administration (FDA).

You may also like

Trending news

Crypto prices